Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749041 | 0.85 | PIK3CD (0.34) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL14749068 | 0.83 | EPHX1 (0.36) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL14752954 | 0.81 | PIK3CD (0.33) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL14752953 | 0.80 | CHRNB2 (0.37) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL21900166 | 0.80 | CHRNB2 (0.37) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL20011843 | 0.75 | SLC6A3 (0.30) | — | |
| SCHEMBL1413457 | 0.74 | GABRR1 (0.36) | GABRR1ACEAKR1C3AKR1C1APLNR | |
| SCHEMBL15683019 | 0.71 | LMNA (0.34) | PIK3CDL3MBTL1 | |
| SCHEMBL28611499 | 0.71 | GABRR1 (0.37) | GABRR1ACEAKR1C3AKR1C1KDM4E | |
| SCHEMBL777224 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259116-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3515903-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| CN-110036006-A | The preparation and use of pyrimidone derivatives | 癌症研究科技有限公司 | 2019-07-19 | — | — | CN | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| EP-2885293-B1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-27 | — | — | EP | disclosed |
| EP-2885293-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica, N.V. (BE) | 2015-06-24 | — | — | EP | disclosed |
| US-8901314-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| WO-2014028803-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PIK3CD 512/4885TLR9 4705/4885TLR8 4590/4885 |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | PIK3CD 727/4885TLR9 3990/4885TLR8 3635/4885 |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1A | PIK3CD 2322/4885TLR9 4535/4885TLR8 4741/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | PIK3CD 753/4885TLR9 4027/4885TLR8 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.